ClinicalTrials.gg
Active, not recruitingNCT06712771Updated May 5, 2026

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

A Phase 3 interventional study of VSA003 and Placebo in Homozygous Familial Hypercholesterolemia (HoFH), sponsored by Visirna Therapeutics HK Limited. Active, not recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Visirna Therapeutics HK Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China — 5 open to participants now, 6 under way, 2 of them phase 3. Homozygous Familial Hypercholesterolemia · China.

Enrollment
3rd of 11
46 · median 20
Started
2024
the only one that year
Phase 3
3 of 12
1 open now
Registered
8th of 12
by date
Lead sponsor
1 of 12
Visirna Therapeutics HK Limited

Among the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 3 in phase 3, and was the 8th registered.

Homozygous Familial Hypercholesterolemia

68 studies on the registry are indexed under Homozygous Familial Hypercholesterolemia; 13 are open to participants now.

Browse Homozygous Familial Hypercholesterolemia studies →

Open to participants now

5 of the 12 studies in Homozygous Familial Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 12 Homozygous Familial Hypercholesterolemia studies recruiting now, 6 (50%) set no upper age limit and 5 (42%) stop at 75 or younger; 8 take children under 18; none take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Homozygous Familial Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

Significant reduction in ANGPLT3 levels is expected to reduce plasma LDL-C and TG levels and may lead to the reduction of risk of coronary heart disease and cardiovascular events associated with hypertriglyceridemia and LDL-C in subjects with persistent dyslipidemia. In this clinical study, the efficacy and safety of VSA003, an RNAi-based therapeutic targeting ANGPTL3, will be evaluated in subjects with HoFH.

03

Conditions studied

  • Homozygous Familial Hypercholesterolemia (HoFH)
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged ≥ 12 years and weighing ≥ 40 kg at the time of ICF signature;
  • Patients with HoFH who meet genetic or clinical diagnosis;
  • Willing to follow a daily low-fat diet for the duration of the study;
  • Receiving stable and tolerable lipid-lowering therapy prior to LDL-C testing during the screening period;
  • Fasting LDL-C ≥ 2.6 mmol/L.

Exclusion criteria

Exclusion Criteria:

  • Have received or are receiving targeted ANGPTL3 treatment within 5 months or 5 half-lives, whichever is longer, prior to screening;
  • Fasting TG ≥ 4.5 mmol/L at screening;
  • Presence of uncontrolled endocrine disease affecting lipids or lipoproteins;
  • Weight change of more than 10% in the 4 weeks prior to randomisation;
  • Initiation of a new dietary plan or significant differences from previous dietary structure and habits within 4 weeks prior to screening;
  • Women who are pregnant (including planned pregnancies) or breastfeeding;
  • Refusal to limit alcohol consumption to moderate limits and below during the study period, specifically no more than 14 units per week;
  • Uncontrolled hypertension (blood pressure > 160/100 mmHg at screening);
  • (NYHA) class IV heart failure or \<30% within 12 months prior to screening;
  • History of major surgery within 12 weeks prior to baseline, or planning to undergo major surgery during the study;
  • Known allergy to any component of the study drug.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    VSA003

    subcutaneous injections

    Drug: VSA003

  • Placebo comparator
    Placebo

    subcutaneous injections

    Drug: Placebo

Interventions

  • DrugVSA003

    subcutaneous injections

    Also known as: AROANG3, Zodasiran

  • DrugPlacebo

    subcutaneous injections

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in serum LDL-C at month 6

    Time frame: At month 6

Secondary outcomes

  1. Percent change and absolute change in serum ANGPTL3 levels from baseline at month 6

    Time frame: At month 6

  2. Percent change and absolute change in serum LDL-C, ApoB, non-HDL-C, VLDL-C, TC and TG levels from baseline

    Time frame: Up to month 6, Up to month 18

  3. Percent change and absolute change in serum HDL-C, ApoC-III, ApoC-II, ApoA-I, ApoA-V and Lp[a] levels from baseline

    Time frame: Up to month 6, Up to month 18

  4. Percentage of patients achieving ≥30% reduction in serum LDL-C from baseline

    Time frame: At month 6, At month 18

  5. Percentage of patients achieving ≥50% reduction in serum LDL-C from baseline

    Time frame: At month 6, At month 18

  6. Number of Participants with Adverse Events

    Time frame: Up to month 6, Up to month 18

  7. Number of Participants with Anti-Drug Antibodies (ADAs) to VSA003 Over Time

    Time frame: Up to month 6, Up to month 18

  8. Correlation between VSA003 serum concentrations and QT intervals

    Time frame: Up to month 6, Up to month 18

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Dec 2025, 13 months.

Of 20 phase 3 interventional studies under Homozygous Familial Hypercholesterolemia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 34. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 2, 2024
StartActual
Nov 27, 2024
Primary completionActual
Dec 31, 2025
CompletionEst.
Dec 30, 2027
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06712771
Lead sponsor
Visirna Therapeutics HK Limited
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Nov 27, 2024
Primary completion
Dec 31, 2025
Completion
Dec 30, 2027 (estimated)
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion